Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety and Efficacy of Brodalumab in Rheumatoid Arthritis
NCT01059448Phase 2Terminated
- Sponsor
- Amgen
- Start
- Jun 2010
- Primary completion
- Apr 2011
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of brodalumab in rheumatoid arthritis (RA), sponsored by Amgen. Started Jun 2010; status: terminated.
02
Drugs
brodalumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01059448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01059448.